Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy

Virology Journal

Volumn 7, Issue , 2010, Pages

  Wu, Chao ^a   Liu, Yong ^a   Zhao, Qi ^a   Chen, Guangmei ^a   Chen, Junhao ^a   Yan, Xiaomin ^a   Zhou, Yi Hua ^a   Huang, Zuhu ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 LIGAND; CD86 ANTIGEN; HEPATITIS B CORE ANTIGEN 18-27 PEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOMETRY; CYTOTOXIC T LYMPHOCYTE; FLUORESCENCE MICROSCOPY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOCYTE CULTURE; B LYMPHOCYTE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION;

HEPATITIS B VIRUS;

ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CD40 LIGAND; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78650376223     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-370     Document Type: Article

References (26)

1. The dendritic cell system and its role in immunogenicity. RM Steinman, Annu Rev Immunol 1991 9 271 296 10.1146/annurev.iy.09.040191.001415 1910679
2. Dendritic cells and the control of immunity. J Banchereau RM Steinman, Nature 1998 392 245 252 10.1038/32588 9521319
3. Origin, maturation and antigen presenting function of dendritic cells. M Cella F Sallusto A Lanzavecchia, Curr Opin Immunol 1997 9 10 16 10.1016/S0952-7915(97)80153-7 9039784
4. Immunotherapy with dendritic cells pulsed by autologous dactinomycin-induced melanoma apoptotic bodies for patients with malignant melanoma. JW Chang JJ Hsieh YC Shen E Ho CK Chuang YR Chen SK Liao JS Chen SP Leong MM Hou NJ Chang CH Wang, Melanoma Res 2009 19 309 315 10.1097/CMR. 0b013e32832b2717 19750589
5. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma. DY Cao JY Yang SQ Yue KS Tao ZS Song DS Wang YL Yang KF Dou, Cell Immunol 2009 259 13 20 10.1016/j.cellimm.2009.05.007 19545862
6. Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response. W Chen Z Zhang M Shi L Chen J Fu F Shi B Zhang H Zhang L Jin FS Wang, Clin Immunol 2008 129 295 303 10.1016/j.clim.2008.07.026 18774748
7. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. CM Coughlin BA Vance SA Grupp RH Vonderheide, Blood 2004 103 2046 2054 10.1182/blood-2003-07-2379 14630810
8. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. JL Schultze S Michalak MJ Seamon G Dranoff K Jung J Daley JC Delgado JG Gribben LM Nadler, J Clin Invest 1997 100 2757 2765 10.1172/JCI119822 9389740
9. Targeting adult and pediatric cancers via cell-based vaccines and the prospect of activated B lymphocytes as a novel modality. CM Coughlin RH Vonderheide, Cancer Biol Ther 2003 2 466 470 14614310
10. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. E Kondo MS Topp HP Kiem Y Obata Y Morishima K Kuzushima M Tanimoto M Harada T Takahashi Y Akatsuka, J Immunol 2002 169 2164 2171 12165546
11. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. RG van der Molen D Sprengers RS Binda EC de Jong HG Niesters JG Kusters J Kwekkeboom HL Janssen, Hepatology 2004 40 738 746 10.1002/hep.20366 15349914
12. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. S Beckebaum VR Cicinnati G Dworacki J Müller-Berghaus D Stolz J Harnaha TL Whiteside AW Thomson L Lu JJ Fung CA Bonham, Clin Immunol 2002 104 138 150 10.1006/clim.2002.5245 12165275
13. Hepatitis B virus-induced defect of moncyte-derived dendritic cells leads to impaired T helper type l response in vitro: mechanisms for viral immune escape. S Beckebaum VR Cicinnati X Zhang S Ferencik A Frilling H Grosse-Wilde CE Broelsch G Gerken, Immunology 2003 109 487 495 10.1046/j.1365-2567.2003.01699.x 12871214
14. Role of B cells in antigen presentation of the hepatitis B core. DR Milich M Chen F Schödel DL Peterson JE Jones JL Hughes, Proc Natl Acad Sci USA 1997 94 14648 14653 10.1073/pnas.94.26.14648 9405667
15. CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. E Kondo L Gryschok N Klein-Gonzalez S Rademacher MR Weihrauch T Liebig A Shimabukuro-Vornhagen M Kochanek A Draube MS von Bergwelt-Baildon, Clin Exp Immunol 2009 155 249 256 10.1111/j.1365-2249.2008.03820.x 19040609
16. Stimulation by means of dendritic cells followed by Epstein-Barr virus-transformed B cells as antigen-presenting cells is more efficient than dendritic cells alone in inducing Aspergillus f16-specific cytotoxic T cell responses. F Zhu G Ramadan B Davies DA Margolis CA Keever-Taylor, Clin Exp Immunol 2008 151 284 296 10.1111/j.1365-2249.2007.03544.x 18005260
17. B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC. R Ivanov T Aarts A Hagenbeek S Hol S Ebeling, Cytotherapy 2005 7 62 73 10.1080/14653240510018055 16040385
18. Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection. SM Akbar N Horiike M Onji, World J Gastroenterol 2006 12 2876 2883 16718812
19. Activation of B cells using Schneider 2 cells expressing CD40L for the enhancement of antigen presentation in vitro. SH Yoon HI Cho TG Kim, Exp Mol Med 2005 37 567 574 16391518
20. B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. H Noorchashm AJ Reed SY Rostami R Mozaffari G Zekavat B Koeberlein AJ Caton A Naji, J Immunol 2006 177 7715 7722 17114442
21. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines. NG Chakraborty L Li JR Sporn SH Kurtzman MT Ergin B Mukherji, J Immunol 1999 162 5576 5583 10228040
22. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. B Salomon JA Bluestone, Annu Rev Immunol 2001 19 225 252 10.1146/annurev.immunol.19.1.225 11244036
23. DNA measurement and cell cycle analysis by flow cytometry. R Nunez, Curr Issues Mol Biol 2001 3 67 70 11488413
24. Specific human cellular immunity to bcr-abl oncogene-derived peptides. M Bocchia T Korontsvit Q Xu S Mackinnon SY Yang A Sette DA Scheinberg, Blood 1996 87 3587 3592 8611681
25. Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro. M Shi S Qian WW Chen H Zhang B Zhang ZR Tang Z Zhang FS Wang, Clin Exp Immunol 2007 147 277 286 10.1111/j.1365-2249.2006. 03281.x 17223969
26. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. A Penna FV Chisari A Bertoletti G Missale P Fowler T Giuberti F Fiaccadori C Ferrari, J Exp Med 1991 174 1565 1570 10.1084/jem.174.6.1565 1720813